SAN FRANCISCO, May 30, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (œOlema, œOlema Oncology, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
SAN DIEGO, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported proof of mechanism in KURRENT-HN, the Company’s Phase 1/2 clinical trial of tipifarnib in combination with alpelisib in patients with HRAS- and/or PIK3CA-dependent head and neck squamous cell carcinoma (HNSCC). The preliminary data are being presented at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium in Barcelona.
Gravity Branding chose a positive outlook when it named Novartis’ latest FDA approved drug Vijoice but also set a deeper meaning.
Novartis recently announced results of an exploratory retrospective biomarker analysis finding that different genetic mutation profiles in tumours harbouring PIK3CA mutation did not affect treatment benefit with Piqray (alpelisib) plus fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer following progression on or after an endocrine-based regimen. Selected as an oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, the retrospective analysis of data from the phase-III Solar-1 study found that the clinical benefit of the Piqray and fulvestrant combination was maintained regardless of genetic alterations in most biomarkers, including ESR1 and genes implicated in resistance to CDK4/6 inhibitors, a statement from Novartis notified.
Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1Â PROS is a spectrum of rare conditions and is characterized by...
London, UK, 23 December 2021 — Today Novartis announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved the marketing authorisation to extend the licence in Great Britain for Piqray (alpelisib) for use in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor positive(HR+), human epidermal growth factor receptor 2 negative(HER2-), locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine-based therapy.
SAN DIEGO, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Kura nOncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical ncompany committed to realizing the promise of precision medicines for nthe treatment of cancer, today announced dose administration for the nfirst patient in KURRENT, the Company’s Phase 1/2 clinical trial of ntipifarnib in combination with alpelisib in patients with HRAS- and/or nPIK3CA-dependent head and neck squamous cell carcinoma (HNSCC).
Novartis today announced important findings from a real-world study evaluating the safety and efficacy of alpelisib for people living with PIK3CA-Related Overgrowth Spectrum (PROS) who received treatment daily for at least 24 weeks. Results from EPIK-P1 showed alpelisib effectively reduced volume of clinically significant PROS-related lesions and improved signs and symptoms in pediatric and adult patients. Results were presented at the European Society of Medical Oncology (ESMO) Virtual Congress 2021 [LBA23].
SAN DIEGO, July 06, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma (HNSCC) whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Tipifarnib is Kura’s farnesyl transferase inhibitor drug candidate currently in a registration-directed trial as a monotherapy in patients with HRAS mutant HNSCC. Novartis’ alpelisib is an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity predominantly against the PI3K? isoform.
DORVAL, QC, Aug. 13, 2020 /CNW Telbec/ - Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that PIQRAY® (alpelisib) is approved and now available in Canada. PIQRAY® in combination with fulvestrant is indicated for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regimen.10 This approval marks the first-ever treatment specifically for HR-positive, HER2-negative metastatic breast cancer with a PIK3CA mutation and is based on results from the pivotal SOLAR-1 clinical trial, which included ten Canadian trial sites and ten Canadian investigators.